[1. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality, 1977B99. J Thromb Haemost 2004; 2:1047B1054.10.1046/j.1538-7836.2004.00710.x]Search in Google Scholar
[2. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594B598.10.1016/0140-6736(92)90874-3]Search in Google Scholar
[3. Roberts HR, Monroe DM, White GC. The use of recombinate factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858B3864.10.1182/blood-2004-06-222315328151]Open DOISearch in Google Scholar
[4. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1997; 55: 638B648.10.1038/clpt.1994.808004880]Search in Google Scholar
[5. Yatuv R, Dayan I, CarmelBGoren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008; 14: 476B48310.1111/j.1365-2516.2008.01741.x18393980]Open DOISearch in Google Scholar
[6. Weimer T, Wormsbächer W, Kronthaler U, et al. Prolonged inBvivo half life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659B66710.1160/TH07-08-052518392323]Search in Google Scholar
[7. Leissinger C, Gringeri A, Antmen B, et al. AntiBinhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684B92.10.1056/NEJMoa110443522047559]Search in Google Scholar
[8. MancoBJohnson MJ, Abshire TC, Schapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535B544.10.1056/NEJMc07262318003967]Search in Google Scholar
[9. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904B1913.10.1111/j.1538-7836.2007.02663.x17723130]Open DOISearch in Google Scholar
[10. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335B134410.1182/blood-2011-08-36913222101900]Search in Google Scholar
[11. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52B57.10.1055/s-0037-1612943]Search in Google Scholar
[12. Mariani G, Kroner B. Immune Tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186B1193.]Search in Google Scholar
[13. Kruez W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with haemophilia A: a prospective longBterm followBup comparing plasmaBderived and recombinant products. Semin Thromb Hemost 2002; 28: 285B 290.10.1055/s-2002-3266412098090]Open DOISearch in Google Scholar
[13. Kruez W. Immune tolerance and choice of concentrates. In: Lee C, ed. Inhibitors in patients with haemophilia. Oxford: Blackwell Science Ltd. 2002; 55B56.10.1002/9780470757260.ch9]Search in Google Scholar
[14. Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia 2001; 17: 11B16.10.1111/j.1365-2516.2010.02337.x20565546]Search in Google Scholar